查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867182

卡納萬病治療市場按治療方法、給藥途徑、分銷管道、最終用戶、治療線、開發商類型、技術和患者年齡層分類 - 全球預測 2025-2032

Canavan Disease Therapeutics Market by Therapy Type, Route Of Administration, Distribution Channel, End User, Therapy Line, Developer Type, Technology, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，卡納萬病治療市場將成長至 8.9437 億美元，複合年成長率為 6.10%。

關鍵市場統計數據
基準年 2024 5.5666億美元
預計年份：2025年 5.9107億美元
預測年份 2032 8.9437億美元
複合年成長率 (%) 6.10%

策略背景及重點：臨床與科學挑戰如何影響卡納萬病下一代療法的研發

卡納萬氏症是一種以天冬胺酸代謝酶缺乏所引起的進行性中樞神經系統海綿狀進行性為特徵的疾病，至今仍是臨床上最具挑戰性的腦白質營養不良症之一。儘管數十年來已對其進行了分子特徵分析，但由於藥物難以穿過血腦障壁、自然病史數據有限以及缺乏特徵明確的患者隊列，治療方法研發一直受到限制。目前的研發現狀反映了一個學習曲線，臨床前模型的預測能力比以往任何時候都更強，近年來載體技術、給藥方案和生物標記開發方面也取得了顯著進展。

載體技術、精準編輯平台以及不斷發展的監管和生產模式的進步將如何重塑卡納萬病治療研發？

隨著基因遞送、精準編輯和輔助藥理學等領域的創新融合，卡納萬病治療格局正在經歷一場變革。載體技術能夠更好地靶向中樞神經系統並降低定向，從而實現更可靠的全身和腦實質內給藥策略。同時，基因組編輯平台的進步使得開發持久有效的治療方法成為可能，而小分子調節劑作為免疫抗原性補充策略，在解決代謝異常和緩解症狀方面仍然發揮著重要作用。

評估2025年美國關稅調整對先進治療藥物供應鏈動態、籌資策略與生產韌性的影響

2025年美國關稅調整對卡納萬病治療生態系統產生了多方面的影響，改變了關鍵材料的採購成本結構和物流模式。由於進口關稅的提高，專用設備、一次性生物反應器零件和先進試劑的供應商面臨到岸成本增加和採購前置作業時間延長的雙重壓力。由於基因治療項目依賴高度特定的原料和跨境供應鏈，這些關稅引發的摩擦導致生產宣傳活動的緩衝時間縮短，並需要尋找替代的籌資策略。

綜合細分分析，闡述治療方法類型、給藥方式、通路、終端用戶環境、開發商類型、技術和患者年齡如何影響策略決策。

了解細分市場的細微差別對於解讀卡納萬病治療方案的治療機會和營運重點至關重要。依治療方式分類的治療方法包括酵素替代療法、基因療法和小分子療法。基因療法的遞送方式根據腺相關病毒（AAV）和慢病毒載體平台而有所不同，而小分子療法可能專注於鋰或N-乙醯半胱胺酸等藥物。給藥途徑是另一個重要方面，包括肌肉注射、靜脈注射和口服，每種途徑對藥物動力學、患者依從性和臨床監測的影響各不相同。通路影響藥物的可及性和依從性，涵蓋醫院藥房、線上藥房和零售藥房，所有這些都與報銷機制和患者支援服務相關。

區域監管差異、生產能力分配和臨床網路成熟度如何影響全球市場的適應性開發和准入策略

區域趨勢將對卡納萬病藥物研發策略、監管互動和病患用藥產生決定性影響。在美洲，臨床專業知識和先進製造能力的集中中心構建了一個強大的生態系統，為早期臨床試驗和商業化計劃提供支持，監管路徑側重於基於已建立的罕見疾病機制的快速核准流程。在歐洲、中東和非洲，法規環境不均衡，先進的臨床網路和不同的報銷制度要求申辦方根據不同地區調整證物材料和用藥策略。在亞太地區，新興的臨床試驗能力、不斷發展的生物技術生態系統以及擴大本地生產的努力，為可擴展且經濟高效的生產創造了極具吸引力的選擇，但監管協調仍然是一項持續的挑戰。

具有競爭力的企業級洞察，揭示科學專長、夥伴關係策略和製造聯盟如何決定專案進度和生態系統合作。

在卡納萬病領域，主要企業在科學研究重點、生產策略和夥伴關係模式方面展現出差異化的發展路徑。一些開發人員強調載體工程和基因組編輯平台的深度，大力投資於臨床前檢驗和載體最佳化，以確保中樞神經系統持續表達和良好的安全性。另一些公司則優先考慮轉化應用的靈活性，將已用於治療卡納萬病的小分子藥物與支持性治療相結合，以減輕症狀負擔並擴大治療窗口，同時推進基因治療計畫的成熟。整體而言，專業生技研發公司與大型製藥公司之間的合作十分普遍，這種合作模式將深厚的科研專長與商業基礎設施和醫保支付方溝通能力結合。

產業領導者提升罕見疾病計畫供應鏈韌性、監管合規性、病人參與和生產規模化的實用方法

產業領導者應採取一系列切實可行的策略，推動複雜的卡納萬病治療藥物的研發和商業化。首先，必須優先考慮供應鏈的韌性。透過對多家供應商進行資格認證、投資建設地域分散的生產能力以及製定穩健的關鍵原料庫存計劃，可以降低專案風險。其次，儘早與監管機構就可接受的替代終點和適應性研究設計進行協調，可以降低臨床實驗風險並提高研發進度的可預測性。第三，將病患權益組織納入通訊協定共同設計和自然史研究，可以提高試驗的相關性，加快病患招募速度，並加強真實世界資料的收集。

策略結論和建議透過透明的混合方法調查方法檢驗，該方法結合了文獻綜合、專家訪談和嚴格的檢驗。

本研究採用混合方法，結合了全面的二手文獻綜述、一手質性訪談和嚴格的交叉檢驗。二手文獻包括同行評審的科學文獻、監管指導文件、會議報告和技術白皮書，用於建立科學和監管背景。一手研究包括對腦白質營養不良症臨床醫生、病毒載體生產專家、監管事務負責人、醫保專家和患者權益倡導者進行結構化訪談，以獲取實踐見解、優先排序標準和實際限制。

最後總結發言指出，需要具備營運韌性、策略協同和實用化協調能力，才能將科學進步轉化為對病人的影響。

卡納萬病有效治療方法的研發，取決於技術創新、以患者為中心的試驗設計以及切實可行的操作執行三者之間的交匯點。載體設計、基因組編輯和輔助藥理學的科學進步已催生出多種可靠的治療途徑，但成功的實用化需要對生產規模、監管策略和患者參與度給予足夠的重視。諸如關稅引發的採購挑戰等短期干擾，凸顯了建構具有韌性的供應鏈和區域生產策略的必要性。同時，監管的靈活性和試驗設計的進步，為在不降低證據品質的前提下加速研發創造了機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對ASPA基因修復的基因療法臨床試驗取得進展
  • 專注於中樞神經系統髓鞘保護的創新小分子化合物
  • FDA快速通道計畫下AAV介導的罕見神經系統疾病療法的監管審查進展
  • 與一家生物技術Start-Ups和學術機構合作，對卡納萬病進行生物標記檢驗
  • 患者權益倡導組織致力於資金籌措並提高公眾對卡納萬病臨床研究的認知。
  • 利用機器學習演算法最佳化卡納萬病酶替代療法的劑量方案
  • 開發用於卡納萬病中樞神經系統標靶化基因轉移的脂質奈米顆粒遞送平台

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 卡納萬病治療市場（依治療方法）

  • 酵素替代療法
  • 基因治療
    • AAV載體
    • 慢病毒載體
  • 小分子療法
    • 鋰
    • N-乙醯半胱胺酸

9. 卡納萬氏症治療藥物市場（依給藥途徑分類）

  • 肌肉內注射
  • 靜脈注射
  • 口服

第10章 卡納萬病治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 卡納萬病治療市場（按最終用戶分類）

  • 診所
  • 居家醫療環境
  • 醫院

12. 卡納萬病治療市場（依治療系列分類）

  • 一線治療
  • 二級治療

第13章 卡納萬病治療藥物市場（按開發商類型分類）

  • 生技公司
  • 製藥公司

14. 卡納萬病治療市場（依技術分類）

  • CRISPR-Cas9
  • 塔倫
  • ZFN

第15章 卡納萬病治療市場（依患者年齡層分類）

  • 成年患者
  • 兒科患者

第16章 卡納萬病治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 卡納萬病治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 各國卡納萬病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Ionis Pharmaceuticals, Inc.
    • Aspa Therapeutics
    • Contera Pharma
    • RegenxBio
    • Novartis AG
    • Biogen Inc.
    • Rocket Pharmaceuticals
Product Code: MRR-99555D550525

The Canavan Disease Therapeutics Market is projected to grow by USD 894.37 million at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 556.66 million
Estimated Year [2025] USD 591.07 million
Forecast Year [2032] USD 894.37 million
CAGR (%) 6.10%

A focused orientation to the clinical and scientific imperatives shaping next-generation therapeutic development for Canavan disease with strategic context

Canavan disease remains one of the most clinically challenging leukodystrophies, characterized by progressive spongiform degeneration of the central nervous system driven by aspartoacylase deficiency. Despite decades of molecular characterization, therapeutic development has been constrained by blood-brain barrier delivery challenges, limited natural history datasets, and the rarity of well-characterized patient cohorts. The current development landscape reflects a learning curve: preclinical models are more predictive than before, and vectorology, dosing paradigms, and biomarker development have advanced materially over the last several years.

As clinical teams translate mechanistic insights into human studies, industry stakeholders must reconcile scientific potential with operational realities. Manufacturing capacity for viral vectors, standardization of outcome measures, and alignment with rare-disease regulatory pathways are immediate priorities. In parallel, patient advocacy groups and clinician networks are increasingly shaping trial design and recruitment strategies, enabling more patient-centric approaches. Taken together, these elements frame a high-stakes but increasingly navigable pathway from bench to bedside for Canavan disease therapeutics.

How advances in vector technology, precision editing platforms, and evolving regulatory and manufacturing paradigms are reshaping Canavan disease therapeutic development

The therapeutic landscape for Canavan disease is undergoing transformative shifts as innovations in gene delivery, precision editing, and supportive pharmacology converge. Vector technologies have evolved to offer improved central nervous system tropism and reduced immunogenicity, enabling more credible systemic and intraparenchymal delivery strategies. Concurrently, advances in genome editing platforms permit exploration of permanent corrective approaches, while small molecule modulation remains relevant as a complementary strategy to address metabolic dysregulation and symptomatic needs.

Regulatory and payer frameworks are also adapting to rare disease realities. Accelerated approval pathways, adaptive trial design options, and expanded access mechanisms are influencing developmental timelines and commercial planning. Meanwhile, manufacturing innovations-such as scalable vector production and modular cell-processing workflows-are de-risking supply constraints that historically impeded progress. These converging shifts are changing how sponsors prioritize programs, allocate capital, and engage with clinical networks, ultimately creating a more dynamic environment for translating promising science into viable therapies.

An assessment of how the 2025 United States tariff adjustments altered supply chain dynamics, procurement strategies, and manufacturing resilience for advanced therapeutics

United States tariff changes implemented in 2025 have exerted a multifaceted influence on the Canavan disease therapeutic ecosystem by altering the cost structure and logistics of sourcing critical inputs. Suppliers of specialized equipment, single-use bioreactor components, and advanced reagents faced elevated import duties that increased landed costs and extended procurement lead times. Because gene therapy programs rely on highly specific raw materials and cross-border supply chains, these tariff-driven frictions translated into tighter scheduling buffers for manufacturing campaigns and a need for alternative sourcing strategies.

In response, sponsors and contract development and manufacturing organizations have accelerated nearshoring initiatives and diversified supplier bases to mitigate supply chain concentration risk. This operational pivot has implications for program budgets and timeline management, as qualification of new suppliers and revalidation of processes require time and investment. At the same time, clinical operations teams have recalibrated inventory strategies for critical supplies to prevent trial disruptions. While tariffs introduced short-term headwinds, they also prompted a strategic reassessment of supply resilience and have catalyzed investments in domestic capacity expansion and procurement agility that could yield longer-term benefits for rare disease program continuity.

Integrated segmentation analysis explaining how therapy modality, delivery approach, distribution, end user settings, developer type, technology and patient age inform strategic decisions

A nuanced understanding of segmentation is essential to interpret therapeutic opportunity and operational priorities across Canavan disease programs. When therapies are categorized by treatment modality, the field includes enzyme replacement therapy, gene therapy, and small molecule therapy; within gene therapy, delivery approaches are differentiated by AAV vector and lentiviral vector platforms, while small molecule programs may focus on lithium or N-acetylcysteine as pharmacologic approaches. Route of administration is another critical axis, encompassing intramuscular, intravenous, and oral modalities, each with distinct implications for pharmacokinetics, patient adherence, and clinical monitoring. Distribution channels shape access and adherence pathways, spanning hospital pharmacies, online pharmacies, and retail pharmacies, all of which interact with reimbursement mechanisms and patient support services.

End user dynamics-clinics, homecare settings, and hospitals-inform both delivery feasibility and real-world evidence generation, while therapy line classification into first-line and second-line treatments determines clinical positioning and payer negotiation strategies. Developer type separates approaches by biotech companies and pharmaceutical companies, with differences in risk tolerance, vertical capabilities, and commercialization reach. Technology platforms such as CRISPR-Cas9, TALEN, and ZFN provide mechanistic differentiation that affects regulatory engagement and intellectual property strategies. Finally, patient age group stratification into adult and pediatric populations drives distinct clinical trial designs, outcome measures, and safety monitoring frameworks. Together, these segmentation dimensions create an interlocking framework that guides program design, clinical development priorities, and commercialization tactics.

How regional regulatory variability, manufacturing capacity allocation, and clinical network maturity influence adaptive development and access strategies across global markets

Regional dynamics have a determinative effect on development strategies, regulatory interactions, and patient access for Canavan disease therapeutics. In the Americas, concentrated centers of clinical expertise and advanced manufacturing capacity underpin a strong ecosystem for early-phase testing and commercialization planning, and regulatory pathways emphasize established rare disease mechanisms for expedited engagement. Europe, Middle East & Africa present heterogenous regulatory environments with pockets of advanced clinical networks and reimbursement variability, prompting sponsors to tailor evidence packages and access strategies region by region. In the Asia-Pacific region, emerging clinical trial capacity, growing biotech ecosystems, and efforts to expand local manufacturing create compelling options for scale and cost-efficient production, although regulatory harmonization remains a work in progress.

These regional distinctions affect everything from trial site selection and patient recruitment to supply chain routing and pricing strategy. As a result, cross-regional planning is now a core competency for sponsors, requiring harmonized data standards, pragmatic regulatory submission planning, and culturally competent patient engagement approaches. Strategic partnerships with regional clinical networks and contract manufacturers can accelerate program timelines while managing regulatory and commercial complexity across distinct geographies.

Competitive company-level insights revealing how scientific specialization, partnership strategies, and manufacturing partnerships define program advancement and ecosystem collaboration

Leading companies operating in the Canavan disease space demonstrate differentiated approaches across scientific focus, manufacturing strategy, and partnership models. Some developers emphasize platform depth in vector engineering and genome editing, investing heavily in preclinical validation and vector optimization to secure durable CNS expression and favorable safety profiles. Others prioritize translational agility by combining repurposed small molecules with supportive therapies to address symptom burden and extend therapeutic windows while gene-based programs mature. Across the board, partnerships between specialized biotech developers and larger pharmaceutical organizations are common, aligning deep scientific expertise with commercial infrastructure and payer engagement capabilities.

Contract development and manufacturing organizations have become indispensable partners, providing scalability and technical know-how for vector production and quality systems. Patient advocacy groups and clinical centers of excellence play a parallel role by contributing to natural history studies, facilitating trial recruitment, and shaping patient-reported outcome measures. Collectively, these stakeholders form an ecosystem in which collaboration, platform specialization, and operational excellence determine program momentum and long-term viability.

Actionable approaches for industry leaders to strengthen supply resilience, regulatory alignment, patient engagement and manufacturing scalability for rare disease programs

Industry leaders should pursue a set of actionable strategies to navigate the complex therapeutic development and commercialization pathway for Canavan disease. First, prioritizing supply chain resilience is essential: qualifying multiple suppliers, investing in regionally diversified manufacturing capacity, and developing robust inventory planning for critical raw materials will reduce program vulnerability. Second, aligning early with regulators on acceptable surrogate endpoints and adaptive trial designs can de-risk pivotal pathways and improve predictability for development timelines. Third, integrating patient advocacy groups into protocol co-design and natural history studies will increase trial relevance, accelerate recruitment, and strengthen real-world evidence capture.

In addition, companies should adopt modular manufacturing and platform-based approaches to maximize vector productivity and reduce per-batch variability, while pursuing cross-program learnings to shorten development cycles. Commercially, tailoring market access strategies to regional payer expectations and distribution infrastructures will improve adoption potential. Finally, investing in biomarker development and long-term follow-up frameworks will create clearer durability and safety narratives, which are critical for payer acceptance and for establishing sustainable reimbursement models. Implementing these actions in a coordinated manner will materially improve the probability of clinical and commercial success.

A transparent mixed-methods research approach combining literature synthesis, expert interviews, and rigorous triangulation to validate strategic conclusions and recommendations

This research employed a mixed-methods approach combining comprehensive secondary literature synthesis with primary qualitative interviews and rigorous cross-validation. Secondary inputs included peer-reviewed scientific literature, regulatory guidance documents, conference proceedings, and technical whitepapers to establish the scientific and regulatory context. Primary research consisted of structured interviews with clinicians specializing in leukodystrophies, manufacturing experts in viral vector production, regulatory affairs professionals, reimbursement specialists, and patient advocacy leaders to capture operational insights, prioritization criteria, and real-world constraints.

Findings were triangulated across data sources to minimize bias, and methodological rigor was maintained through standardized interview guides, anonymized respondent coding, and thematic analysis to distill convergent insights. Quality assurance included expert review by senior analysts with domain experience and iterative validation of conclusions against emerging public disclosures. Where appropriate, sensitivity checks and scenario mapping were used to test the robustness of strategic recommendations. The methodology emphasizes transparency, reproducibility, and a clear linkage between evidence and strategic conclusions.

Concluding perspectives on the imperative of operational resilience, strategic collaboration, and translational alignment to convert scientific advances into patient impact

Developing effective therapies for Canavan disease sits at the intersection of technical innovation, patient-centered trial design, and pragmatic operational execution. Scientific progress in vector design, genome editing, and supportive pharmacology has created multiple credible therapeutic avenues, but successful translation requires deliberate attention to manufacturing scale, regulatory strategy, and patient engagement. Short-term disruptions such as tariff-induced procurement challenges have underscored the need for resilient supply chains and regional manufacturing strategies, while advances in regulatory flexibility and trial design create opportunities to accelerate development without compromising evidence quality.

In summary, the ecosystem is poised for meaningful progress provided stakeholders align on robust operational frameworks, invest in manufacturing and biomarker infrastructure, and deepen collaboration with clinical and patient communities. These elements together can transform promising scientific advances into durable clinical options for patients living with Canavan disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in gene therapy clinical trials targeting ASPA gene restoration
  • 5.2. Innovative small molecule compounds focusing on myelin preservation in the central nervous system
  • 5.3. Regulatory review progress of AAV-mediated therapies for rare neurological disorders in FDA fast track programs
  • 5.4. Collaborations between biotech startups and academic institutions for biomarker validation in Canavan disease
  • 5.5. Patient advocacy initiatives driving increased funding and awareness for Canavan disease clinical research
  • 5.6. Application of machine learning algorithms to optimize dosing regimens for enzyme replacement therapy in Canavan disease
  • 5.7. Development of lipid nanoparticle delivery platforms for targeted central nervous system gene transfer in Canavan disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Canavan Disease Therapeutics Market, by Therapy Type

  • 8.1. Enzyme Replacement Therapy
  • 8.2. Gene Therapy
    • 8.2.1. Aav Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Small Molecule Therapy
    • 8.3.1. Lithium
    • 8.3.2. N-Acetylcysteine

9. Canavan Disease Therapeutics Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral

10. Canavan Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Canavan Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Canavan Disease Therapeutics Market, by Therapy Line

  • 12.1. First-Line
  • 12.2. Second-Line

13. Canavan Disease Therapeutics Market, by Developer Type

  • 13.1. Biotech Companies
  • 13.2. Pharma Companies

14. Canavan Disease Therapeutics Market, by Technology

  • 14.1. Crispr-Cas9
  • 14.2. Talen
  • 14.3. Zfn

15. Canavan Disease Therapeutics Market, by Patient Age Group

  • 15.1. Adult Patients
  • 15.2. Pediatric Patients

16. Canavan Disease Therapeutics Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Canavan Disease Therapeutics Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Canavan Disease Therapeutics Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Ionis Pharmaceuticals, Inc.
    • 19.3.2. Aspa Therapeutics
    • 19.3.3. Contera Pharma
    • 19.3.4. RegenxBio
    • 19.3.5. Novartis AG
    • 19.3.6. Biogen Inc.
    • 19.3.7. Rocket Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CANAVAN DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CANAVAN DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANAVAN DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY LITHIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY N-ACETYLCYSTEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PHARMA COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY CRISPR-CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY DEVELOPER TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST CANAVAN DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST CANAVAN DISEAS